Behavioral changes in response to feeding pancreatic-like enzymes to exocrine pancreatic insufficiency pigs.
Behavioral changes during pancreatic enzyme therapy have never been studied. The present study investigated behavioral changes in exocrine pancreatic insufficiency (EPI) pigs when their feed was supplemented with pancreatic-like enzymes of microbial origin. A crossover design study was used to test the effect of enzyme supplementation in 2 × 4 EPI pigs that underwent pancreatic duct ligation (PDL). After 40 d of adaptation, the study commenced, comprising 2 control and 2 enzyme feeding periods of 10 d each in sequence. On days 7 and 10 of each experimental period, behavior was monitored for 24 h and feed consumption and BW were recorded. Behavioral observations focused on the pigs' activity-- lying down or passive, or sitting, or standing or active--and were expressed as percentage activity for 24 h. During the adaptation period, BW gain was completely inhibited after PDL whereas for the entire study period, the body weight increased from 10.5 ± 1.1 to 14.0 ± 1.4 kg (P < 0.01). Exocrine pancreatic insufficiency pigs were more active when fed the enzymes (21 vs. 18% per 24 h; P < 0.01). Microbial enzyme supplementation not only improved the growth of the EPI pigs but it also increased their activity. This behavior change contradicts the generally accepted norm that satiety evokes by digestion and subsequent nutrients absorption reduces human or animal motility.
Department of Biology, Lund University, 223 62 Lund, Sweden. Stefan.Pierzynowski@biol.lu.se
S
S
Pierzynowski
P
P
Swieboda
R
R
Filip
K
K
Szwiec
J L
JL
Valverde Piedra
D
D
Gruijc
O
O
Prykhodko
O
O
Fedkiv
D
D
Kruszewska
J
J
Botermans
J
J
Svendsen
G
G
Skibo
T
T
Kovalenko
I
I
Osadchenko
K
K
Goncharova
G
G
Ushakova
B
B
Weström
D000681:Amylases / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001230:Aspergillus / Q000201:enzymology; D016956:Burkholderia cepacia / Q000201:enzymology; D018592:Cross-Over Studies; D010188:Exocrine Pancreatic Insufficiency / Q000188:drug therapy / Q000662:veterinary*; D008049:Lipase / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D010447:Peptide Hydrolases / Q000008:administration & dosage / Q000494:pharmacology*; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy*
D008049:Lipase; D000681:Amylases; D010447:Peptide Hydrolases